Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
cardiologists heart doctors heart research heart data

Colchicine reduces risk of some TAVR complications

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.

pharmaceutical drug approval process

New drug candidate for AFib fails in first-in-human trial—in fact, it made matters worse

Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful. 

Compensation for U.S. cardiologists is up across the board, according to a recent survey published by MedAxiom, an American College of Cardiology company. The report identified similar trends for cardiovascular surgeons, highlighting the country’s high demand for all heart specialists in 2024 and beyond.

New gene therapy for rare heart condition gains FDA’s fast track designation

Catecholaminergic polymorphic ventricular tachycardia is a rare, potentially fatal heart rhythm disorder. A new gene therapy candidate from Solid Biosciences is now one step closer to FDA approval. 

Thumbnail

Widespread use of polypills could prevent up to 72 million heart disease deaths

Targeting high-risk patients with single-pill combination therapies, also known as polypills, could change healthcare on a global scale, according new data published in the Journal of the American College of Cardiology. 

Medtronic’s MiniMed 780G automated insulin delivery system

Medtronic receives key approvals for automated insulin pump

The company's automated insulin pump can now be used to treat more patients thanks to an expanded CE mark approval. Could updates from the FDA be next?

The American Heart Association (AHA) has launched a nationwide data-driven research competition to uncover how inflammation contributes to cardiovascular risk and how it is currently addressed in clinical practice. The initiative, called the Systemic Inflammation Data Challenge, invites data scientists, clinicians, and researchers to leverage advanced analytics and electronic medical record (EMR) data to better understand the impact of systemic inflammation on atherosclerotic cardiovascular disease.

AHA data challenge explores links between inflammation and heart disease

Are care teams doing enough to take on inflammation? The American Heart Association hopes this new research initiative can help answer that question, and many others. 

vitamin d supplement heart health CVD

Yes, researchers argue, vitamin D supplements help protect the heart

The ongoing debate continues. The team behind this latest analysis pointed to more than 40 years of research to make its point.

Bayer finerenone Kerendia heart failure MOONRAKER

FDA approves Bayer's finerenone to treat wide range of heart failure patients

Finerenone, sold by Bayer under the brand name Kerendia, is now approved in the United States for the treatment of HFmrEF and HFpEF. The drug has already been used for years to treat patients with chronic kidney disease and type 2 diabetes.

Displaying 17 - 24 of 374
Design by Adaptive Theme